Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Jan Lycke, Clas Malmeström et al.|Annals of Neurology|2010Cited by 347
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MSClas Malmeström, Jan Lycke, Sara Haghighi et al.|Neurology|2003Cited by 318
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre studyJens Kühle, A. Martinez, Éric Thouvenot et al.|Multiple Sclerosis Journal|2015Cited by 298
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosisMarkus Axelsson, Jan Lycke, Clas Malmeström et al.|Journal of Neurology|2010Cited by 192
Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long‐term outcome in patients with autoimmune encephalitisRadu Constantinescu, Henrik Zetterberg, David Krýsl et al.|European Journal of Neurology|2016Cited by 58